FDA denies petitions on synthetic peptides
The US Food and Drug Administration (FDA) has simultaneously denied citizen petitions filed by Amneal and Novo Nordisk that sought to block respectively approvals for generic and follow-on versions of Eli Lilly’s Forteo (teriparatide) and the Danish originator’s liraglutide products containing synthetically derived active substances.
You may also be interested in...
Amphastar will not be receiving approval in 2022 for its proposed generic version of Eli Lilly’s Forteo (teriparatide) peptide for the treatment of osteoporosis, after the FDA told the company it could not issue an approval at this stage.
In a dramatic twist, Gilenya ANDA sponsors are now unable to launch their generic products in the US after the US Supreme Court intervened in favor of originator Novartis, superseding the US Federal Circuit.
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.